Drugs / SCRI-CAR19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02028455 | Feb 2014 → Aug 2021 overdue | B-cell acute lymphoblastic leukemia | Seattle Children's Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCRI-CAR19 | “This study reports outcomes of Pediatric Leukemia Adoptive Therapy 02 (PLAT-02), a phase 2 trial of SCRI-CAR19, a second-generation chimeric antigen receptor (CAR) T-cell...” PMID 40233328 ↗ Aug 2025 |
| Action | Deplete | “The CAR enables the T cell to recognize and kill the leukemic cell through the recognition of CD19” NCT02028455 ↗ |
| Modality | Cell therapy | “a second-generation chimeric antigen receptor (CAR) T-cell product” PMID 40233328 ↗ Aug 2025 |
| Target | CD19 | “a second-generation CD19-specific CAR” PMID 35580141 ↗ Jul 2022 |